Off-Label Therapeutic Potential of Crisaborole

Makins, Caitlyn; Sanghera, Ravina; Grewal, Parbeer

doi:10.1177/1203475420909794

Cited by 7 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apremilast is an oral PDE4 inhibitor that has been used for severe LP in adults so it would make sense to try topical Crisaborole in pediatric LP. [3][4][5][6][7] In our case, the beneficial response and well tolerance have suggested Crisaborole to be a novel therapeutic option for LP. Further investigations are warranted to confirm the efficacy of Crisaborole in treating LP.…”

mentioning

confidence: 58%

“…Crisaborole has been reported to increase intracellular level of cyclic adenosine monophosphate via inhibiting phosphodiesterase-4, thus resulting in decreased proinflammatory cytokines, including IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-13, and IL-17. 5,6 Crisaborole has been approved for treating atopic dermatitis, while accumulating evidence have suggested clinical efficacy for psoriasis, seborrheic dermatitis, vitiligo, alopecia areata and other inflammatory diseases. 6 So far, Crisaborole has not been reported in the treatment of LP.…”

mentioning

confidence: 99%

“…5,6 Crisaborole has been approved for treating atopic dermatitis, while accumulating evidence have suggested clinical efficacy for psoriasis, seborrheic dermatitis, vitiligo, alopecia areata and other inflammatory diseases. 6 So far, Crisaborole has not been reported in the treatment of LP. Apremilast is an oral PDE4 inhibitor that has been used for severe LP in adults so it would make sense to try topical Crisaborole in pediatric LP.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Successful treatment of pediatric lichen planus with topical Crisaborole

Yang

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Lichen planus (LP) is a chronic inflammatory disorder affecting skin, mucous membranes, hair follicles and nails. The treatment of LP in children is challenging due to limited therapeutic options. Here, we present one child with linear LP and nail involvement, who exhibited complete response to topical Crisaborole treatment. A 5-year-old girl presented with a 3-year history of progressive dark red papules and plaques along the Blaschko's line on right lower limb.The rash affected the right shank at first, then extended to the dorsum of right foot along a line, and 6 months later toenail of the first right toe was affected, with longitudinal ridging, fissuring, and distal splitting (Figure 1A). No related family history or trauma were reported. The patient received topical corticosteroids and tacrolimus with partial response, while the lesions relapsed when the medications discontinued. Onychomycosis was ruled out by direct microscopic examination and fungal culture. Dermoscopy revealed F I G U R E 1 The skin lesions of the child. Toenail: longitudinal ridging, fissuring and distal splitting. Dark red papules and plaques on dorsum of foot (A). Lesions began to improve 2 months later (B), improved significantly after 5 months (C), and completely resolved after 10-month treatment (D).Hongzheng Lu and Rui He contributed equally to this work.

show abstract

mentioning

confidence: 58%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Successful treatment of pediatric lichen planus with topical Crisaborole

Yang

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…11 However, it is currently only approved for the treatment of mild-tomoderate atopic dermatitis in adults and children greater than two years of age in China. 12 Several studies have indicated that crisaborole has good therapeutic effects on some other inflammatory dermatoses such as psoriasis and vitiligo 13 as well as hypertrophic lesions like neurodermatitis. 14 Therefore, crisaborole may have a great potential for other hypertrophic lesions.…”

Section: Discussionmentioning

confidence: 99%

Knuckle Pads Successfully Treated with 2% Crisaborole Ointment Combined with Triamcinolone Acetonide and Neomycin Plaster: A Case Report

Liang¹,

Liang²,

Huang³

et al. 2023

CCID

View full text Add to dashboard Cite

Knuckle pads (KPs) are benign hyperkeratotic fibrous thickening skin disorder characterized by nodules or plaques located on the extensor surface of the joints. However, there are no specific treatments for KPs so far. Here, we reported a case of KPs successfully treated with 2% crisaborole ointment combined with triamcinolone acetonide and neomycin plaster. This combined therapy might be a new therapeutic option for KPs.

show abstract

“…Crisaborole was approved in 2016 by the Food and Drug Administration for the treatment of AD in adult patients and was launched in 2017. The drug has been proposed also for the treatment of recalcitrant palmoplantar psoriasis [ 13 ] and, off-label, for psoriasis, seborrheic dermatitis, vitiligo, and inflammatory linear verrucous epidermal nevus [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Skin Retention of Crisaborole after Topical Application

et al. 2020

View full text Add to dashboard Cite

Crisaborole, a nonsteroidal phosphodiesterase 4 inhibitor, represents the first nonsteroidal medication approved for the treatment of atopic dermatitis in over a decade. In this work, crisaborole skin permeation and retention was studied in vitro from a 2% ointment using porcine skin as barrier. Crisaborole was also characterized in terms of thermal behavior, solubility, and logP. Control experiments were performed also on tape stripped skin to clarify the role of stratum corneum in drug partitioning and permeation across the skin. The results obtained indicate that crisaborole accumulates into the skin in considerable amounts after application of a topical lipophilic ointment. Crisaborole shows more affinity for the dermis compared to the epidermis despite its relatively high value of partition coefficient; stratum corneum analysis revealed a low affinity of the drug for this skin layer. Skin penetration across hair follicles or sebaceous glands can be a reason for the high dermis retention and is worth further investigation. The comparison with data obtained from a solution in acetonitrile suggests that the formulation plays a certain role in determining the relative distribution of crisaborole in the skin layers and in the receptor compartment.

show abstract

Off-Label Therapeutic Potential of Crisaborole

Cited by 7 publications

References 23 publications

Successful treatment of pediatric lichen planus with topical Crisaborole

Successful treatment of pediatric lichen planus with topical Crisaborole

Knuckle Pads Successfully Treated with 2% Crisaborole Ointment Combined with Triamcinolone Acetonide and Neomycin Plaster: A Case Report

In Vitro Skin Retention of Crisaborole after Topical Application

Contact Info

Product

Resources

About